Submission 059 Connect with us: Freecall 1800 454 363 www.kidney.org.au







11th July 2018

Committee Chair HCDSFDVPC Parliament House George Street Brisbane OLD 4000

Dear Sir/Madam,

Kidney Health Australia National Office / Victoria 125 Cecil Street South Melbourne VIC 3205

GPO Box 9993 Melbourne VIC 3001

T: +61 3 9674 4300 info@kidney.org.au

The Australian Kidney Foundation Trading as Kidney Health Australia ABN 37 008 464 426 I Charity No. CH 0614

Patron-in-Chief His Excellency General The Honourable Sir Peter Cosgrove AK MC (Retired)

Patrons Lady Margaret Brabham Mr Normie Rowe AM I'm writing on behalf of Kidney Health Australia to state our position on the issues before the current inquiry into pharmacy in Queensland.

Kidney Health Australia is a national not–for-profit organisation dedicated to helping people with kidney disease, with a view to improving their health outcomes and quality of life, and that of their families and carers.

Our concerns centre on the questions concerning pharmacy ownership which have been put forward by the inquiry. Kidney Health Australia is supportive of the current model of community ownership of pharmacies in Queensland, and in every state of Australia.

Our constituents are often elderly, and they regularly suffer from multiple comorbidities. They require specialised attention, care and advice on the medications, and the interactions between these medications. They also need preventative care, such as blood pressure and blood glucose monitoring. These specialised needs necessitate individual and careful attention, which we do not believe they would adequately receive at a corporatised pharmacy. Our experience with community pharmacists gives us confidence that they provide the service and care people living with kidney diseases require.

We are also very concerned about ensuring access to a variety medicines for our constituents. Kidney diseases are complicated conditions requiring a variety of pharmaceutical therapies. We are concerned that in a deregulated environment, pharmacies which are operated solely for the profit of corporate shareholders may be disincentivised from carrying the range of medicines our constituents may require. Access to medicines is of particular concern in rural and remote Queensland, where pharmacies may even disappear in a deregulated landscape.

Finally, we believe that changes to the laws governing ownership may break down the important relationships pharmacists have built with our constituents over many years. With pharmacists no longer owning their own businesses, there may be higher turnover in pharmacies, making it harder for people living with kidney disease to build strong relationships to ensure continuity and quality of care. The holistic approach to care that we have witnessed in community pharmacies may be at risk, as patients become simply retail customers for corporate stores.

Changes in the law in Queensland will be viewed by other states, so the burden on this inquiry is significant. We believe that this committee must summarily reject deregulation of



ownership laws in Queensland, to protect the community pharmacy as an important health destination for those suffering with kidney disease, and countless others.

Regards,

Lisa Murphy Interim CEO

Donunny

Kidney Health Australia